Top Tech Companies (84)
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies. Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach. Gene vectors are the key for enabling gene therapies to reach a wider range of diseases and patients. Success in gene therapy relies on the vector’s ability to safely and precisely deliver a gene payload to the intended target cells and tissues. The efficacy of gene therapies, however, is currently limited by the roster of naturally occurring vectors, which are not optimized for disease treatment. To solve this problem and realize the full potential of gene therapy, Dyno is building its portfolio of proprietary AAV vectors, and working with licensing partners to build targeted AAV vectors enabling treatments in a wide range of disease areas and indications.
SiPhox is a high-impact startup in Burlington, MA integrating microfluidics, biochemistry and Silicon Photonics to miniaturize proteomics. Silicon Photonics is a platform technology for optics miniaturization that has revolutionized the data center industry over the last two decades. SiPhox’s photonic chips enable us to provide 100x smaller, 100x lower cost, highly scalable, multiplexed diagnostics. Founded in February 2020, SiPhox has expanded into an over 7000 sq. ft. lab & office space, raised $8.5 million (seed round, from backers such as Y-combinator and Khosla Ventures), and we are tirelessly working to scale our team and bring our product to market.
CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
CELLINK is a global leader in developing and delivering life-science solutions, equipping hundreds of labs and thousands of scientists worldwide with cutting-edge technologies that fuel groundbreaking scientific breakthroughs. With a commitment to quality and innovation, our bioprinters, imaging systems and bioinks have contributed to revolutionary advancements in academic and clinical medicine. We strive to push the limits of what is possible in regenerative medicine and pharmaceutical development, inspiring and empowering collaborators to expand their horizons and overcome any challenge they face. We are striving to enable scientists around the globe that are doing groundbreaking research.
We work at the intersection of design, biology and engineering – developing new technologies, products & applications that emulate living human biology. Our systems are enabling a new era of precision medicine and personalized health applications. Our founding team pioneered the original human “Organs-on-Chips” technology during their residency within the Wyss Institute for Biologically Inspired Engineering at Harvard University. Organ-Chips - such as the lung, liver, brain or kidney - are micro-engineered environments lined with living human cells and tissues. Each chip recreates the natural physiology and mechanical forces that cells experience within the human body.
AG Mednet’s technology solves critical problems for the pharmaceutical, biotechnology and medical device markets. As the leading partner for endpoint/adverse event adjudication and imaging data collection and QC, we work with the world’s top pharmaceutical companies and CROs.
nirrin is developing sensors and analytics to enable the next generation of biological manufacturing. Using near-infrared spectroscopy we are able to attain real-time, reliable measurements of critical bioprocess parameters. We are primarily focused on applications within the biopharma industry however our technology has the potential to be used across the life sciences. Our small but passionate team is currently working on integrating novel near-infrared sensors with other data sources to provide process control for cell culture. We are looking for a developer with a strong design background to work with the engineering team on the next generation user interface for our data acquisition and analytics software.
Edge Embossing produces disposable plastic parts that become medical devices. Our customers are other biotech companies and researchers who are developing next-generation products for applications like early detection of cancer or HIV or DNA sequencing. We wake up every day knowing we're making the world a better place.
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a number of inherent challenges. Matterworks is developing a novel alternative methodology that activates deep learning (DL) for analytical chemistry, to remove the constraints imposed by the requirement for human-interpretable data. Matterworks is on a mission to democratize metabolomics and catalyze its widespread adoption and integration into the life sciences. Our view is very simple: solving metabolomics will advance all of the life sciences industries.
SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space. Where lab construction can take 9 to 12 months in the traditional process, we deliver personalized and effective lab workflow environments in about 4 weeks. This huge reduction in time means member teams are starting sooner and results are delivered faster. We continue to compound this time savings with our proactive operational support and ability to pivot and change lab space quickly as member science evolves and lab needs change. We love what we do - our members are shaping the future and we are proud to help them do it! We currently have locations in the MIT area of Cambridge, at Innovation Square in the Boston Seaport, in the hot new development at Boston Landing, and in South San Francisco. Visit our website to request a tour.
Medidata is leading the digital transformation of life sciences with the world's most-used platform for clinical development, commercial and real-world data. Powered by artificial intelligence and delivered by #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic
JoVE is the world-leading producer and provider of science video solutions with the mission to improve scientific research and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning. Our institutional clients comprise over 1,000 universities, colleges, and biopharma companies, including such leaders as Harvard, MIT, Yale, and Stanford.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), with the potential to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology, and diseases of the central nervous system. For more information about Entrada, please visit www.entradatx.com.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
